Changes of macular pigment optical density in elderly eyes: a longitudinal analysis from the MARS study
© The Author(s). 2016
Received: 26 February 2016
Accepted: 4 May 2016
Published: 1 June 2016
Macular pigment (MP) has been related to the occurrence of age related macular degeneration (AMD). We investigated prospectively in eyes of elderly individuals how magnitude and spatial distribution of MP had changed after 4 years.
The study included 380 eyes from 237 participants of the Münster Ageing and Retina Study cohort which were free of advanced stages of AMD. MP optical density (MPOD) was measured in density units (D.U.) at eccentricities of 0.25°, 0.5°, 1.0° and 2.0° from the fovea using dual-wavelength autofluorescence; ring-like MP distributions were identified from MP density profiles. Changes were assessed with mixed linear models.
The study participants’ mean age at baseline was 70.5 years. Early AMD was present in 150 study eyes (39.5 %) and a ring-like distribution of MPOD was found in 87 study eyes (22.9 %). After a median follow-up time of 3.96 years, the MPOD averaged over all eyes was slightly raised at the central fovea (from 0.658 to 0.670 D.U. (relative change +1.8 %), p = 0.08) and most markedly at 2.0° (from 0.157 to 0.172 D.U. (+9.5 %), p < 0.001). Multivariate analyses, adjusting for sex, body mass and carotenoid supplement intake, revealed that MPOD increments, at any distance from the fovea, were slightly less pronounced in older eyes. Serum concentrations of lutein at follow-up, presumably reflecting recent intake of antioxidant supplements, raised MPOD levels significantly at 1.0° and 2.0° (both p < 0.01) but not in the central fovea. Early AMD at baseline and ring-like MPOD distribution did not significantly impact on MPOD changes over time. A ring-like spatial distribution of MPOD persisted in over 80 % of the affected eyes.
Overall, the magnitude and spatial arrangement of MPOD was remarkably stable over time in elderly eyes. Significant MPOD rises in perifoveal regions probably indicate effects of lutein containing supplements. The persistence of ring-like MPOD distributions over time seems to suggest their determination by anatomical structures.
KeywordsAge-related macular degeneration Macular pigment optical density Two-wavelength autofluorescence Prospective study
Recent research has shown that the occurrence and progression of age-related macular degeneration (AMD), the leading cause of legal blindness among the elderly population in industrialized countries , is mainly influenced by demographic, environmental and genetic factors [2–4]. The level of macular pigment in the central retina is thought to also have an impact on AMD, however, the precise roles and mechanisms of this process are not yet clearly understood [5, 6]. Commonly, lutein meso-zeaxanthin and zeaxanthin, known to accumulate in the macula as macular pigment (MP)  and having antioxidant and light-screening properties for short wavelengths, are hypothesized to protect the eye against the development of various degenerative retinal diseases, including AMD .
There is presently some debate as to whether a loss of MP is the result of progressed AMD or whether it is a cause . It seems conceivable that degenerative processes cause impairments in transport and storage of lutein and zeaxanthin resulting in decreased MP in the retina . On the other hand, a reduced availability and potentially also storability of carotenoids in the retina may independently lead to the degeneration of functional retinal tissue. Zeimer et al.  demonstrated that, after oral supplementation with lutein and zeaxanthin, an increase in MPOD can be detected only in areas where MPOD had been measurable before in persons with macular telangiectasia. Supplementation did not produce an increase in areas where MPOD had been lacking at baseline. These results are compatible with the hypothesis that MP is stored in retinal tissue structures that are characteristic of an individual and that determine also the spatial patterns of MPOD distribution : supplementation can therefore increase MPOD levels only where such storage facilities were pre-existing. Interestingly, ring-like distributions of MPOD appear not to be affected by supplementation of lutein/zeaxanthin . According to Tariq et al.  such ring-like patterns are highly inheritable and constant in individuals. These results support the idea that genetically determined structural components are responsible for the storability and availability of MP in the macula and that successful supplementation with lutein or zeaxanthin always depends on macular microanatomy. Our recent study using optical coherence tomography supports such a concept .
It is also not entirely clear in which tissue compartments the MP is stored. It is known to primarily accumulate in the inner plexiform layer and the long cone receptor axons (Henle’s fibres) , and more recent studies have attributed Müller cells with the trafficking and storage of MP within the retina . Thus, it has been hypothesized that low levels or loss of MP may be causal to the dysfunction or destruction of Müller cells. The latter may be associated with the ring-like MPOD distribution that is found in a certain proportion of retinae .
To further elucidate these relationships, we investigated whether the contents and the distribution patterns of MP change over time with the ageing of elderly individuals . The measurement of its optical density (MPOD) served as a non-invasive method of quantitative MP assessment and it was prospectively analysed in a cohort of elderly Caucasian individuals who were followed for 4 years.
Data were obtained from participants of the Münster Ageing and Retina Study (MARS), a longitudinal study designed to identify medical, environmental and genetic factors with implications for the pathogenesis and progression of early AMD [17, 18]. Eligibility criteria and examination protocols have been described in detail before [4, 17, 19]. In brief, patients were self-selected ophthalmology patients residing in the Münster region in North-Western Germany. Patients had to be aged between 60 and 80 years by the time the study started, had to have early AMD in at least one eye and no contraindications to pupil dilatation, no advanced cataracts or other factors impeding clear visualization of the central retina. Additionally, a convenience sample consisting of spouses or friends of study participants and of other volunteers that were free of AMD, were included as a comparison group. All participants were of Caucasian origin.
The cohort baseline examinations (MARS I) of 1060 participants took place from June 2001 to October 2003. The first cohort follow-up (MARS II) was carried out between November 2003 and August 2006 with 828 participants attending (85.5 % of those eligible), of whom 722 had gradable fundus photographs in both eyes. Between 2007 and 2009, after a median time of 3.96 years, we re-examined 492 participants (MARS III, participation 75.1 % of those eligible).
At each study visit, participants were interviewed by trained staff members using mostly identical, standardized questionnaires. Detailed information was obtained on demographic characteristics, smoking, lifestyle, medical history, and the current use of medications and vitamin supplements, in particular those containing the carotenoids L and/or Z. Ophthalmological examinations were performed to determine the best corrected visual acuity (Early Treatment Diabetic Retinopathy Study charts) and by using slit-lamp microscopy. The spherical equivalent refractive error in each eye and the number of pseudophakic eyes were documented.
Stereoscopic digital fundus photography was performed at an angle of 30° in both eyes, centred on the fovea. The grading of AMD stages was performed according to the Rotterdam Classification System  as described in detail before [2, 18]. The range of AMD signs was stratified into five severity stages: stage 0, no sign of AMD or hard drusen (<63 μm) only; stage 1, soft, distinct drusen (≥63 μm) only, or pigment epithelium changes only, no soft drusen (≥63 μm); stage 2, soft, indistinct drusen (≥125 μm) only, or soft distinct drusen (≥63 μm) with pigment epithelium changes; stage 3, soft, indistinct drusen (≥125 μm) with pigment epithelium changes; and stage 4, atrophic or neovascular AMD. Eyes were classified as having no AMD (stage 0 or 1), early AMD (stages 2–3) or late stage AMD (stage 4). All baseline and follow-up ophthalmologic examinations were conducted by specifically trained medical staff whose performance was regularly certified. The follow-up visits involved the same examinations as the baseline (MARS I) visits [16, 19] plus additional components such as, e.g., MPOD measurements which were included in MARS II and MARS III.
AMD was diagnosed in eyes with dilated pupils based on presence and severity of retinal lesions.
The two-wavelength autofluorescence (AF) method for measuring MPOD has been previously described [7, 21–24]. Briefly, it is based on the AF of lipofuscin, which is present in the retinal pigment epithelium (RPE) cells. Lipofuscin can be excited in vivo between 400 and 580 nm to emit its fluorescence in the 500–800 nm spectral range, whereas MP absorbs blue-light for wavelengths shorter than 550 nm, with a peak absorbance of 460 nm. In the fovea, excitation light within the absorption range of MP is partially absorbed by the carotenoids, resulting in an area of reduced fluorescence. In order to measure the MPOD, the dual-wavelength approach of the AF method compares results from two excitation wavelengths that are differentially absorbed by the MP. Therefore, the dual-wavelength technique takes account of the non-uniform distribution of lipofuscin in the RPE but assumes that the shape of the excitation spectrum is constant over the macular area .
In our analyses, quantitative imaging was performed using a retinal angiograph (Heidelberg Retina Angiograph HRA 1; Heidelberg Engineering, Heidelberg, Germany), modified for the measurement of macular pigment. Excitation wavelengths used were 488 nm (well absorbed by MP) and 514 nm (minimally absorbed by MP). This method has been used in clinical studies and was described in detail before . MPOD measurements were added to the examination procedures during MARS II and were subsequently also obtained in the participants of MARS III. All MPOD measurements were performed by at least two trained investigators using the same testing device and protocol throughout. Subjects with AF images of inadequate quality (n = 83) (most commonly due to insufficient fixation by the study subjects) were excluded as described before .
MP optical density profile and ring-like structure
In consistency with our previous research on spatial distribution of MP we distinguished between eyes with and without ring-like MPOD structures and a third group of eyes with an intermediate structure [11, 16, 19]. Measurement of spatial distribution has been described previously in detail. In brief, we analyzed the MP optical density maps and the radial density profiles. The latter were generated and graphically displayed by plotting the mean MPOD values that were calculated for each radius around the fovea in distances of up to 8°, displaying a profile of grey scale values comparable to a cross-sectional cut through the foveola. In eyes where the fovea could not be defined automatically as the center of the Gaussian distribution fitted to the MPOD map, the center of the fovea was defined manually (Additional file 1: Figure S1).
Ring-like structures were defined as density profiles showing bimodal patterns consisting of a central peak of MPOD followed by a decline and a secondary peak of increased density on the slope of the profile. In those cases where the distribution of MPOD showed neither a strictly monotonic decline from the foveola to the periphery nor an explicit ring-like pattern, such eyes were labelled as having “intermediate distributions” and were treated as a third group of eyes besides those distinctively categorized as with or without ring-like structures .
For this study, we present the mean MP optical density averaged along an annulus with retinal eccentricity of 0.25°, 0.5°, 1.0° and 2.0° degrees and width of one pixel each. MPOD results are reported in dimensionless density units (D.U.).
We used self-reports on the use of lutein and zeaxanthin (L/Z) containing vitamin supplements. These reports are highly variable due to the availability of an enormous amount of different preparations sold over the counter. Additionally, serum concentrations of lutein and zeaxanthin measured at the follow-up visit of MARS III helped to account for unmeasured lutein and zeaxanthin supplies at follow-up.
Unadjusted comparisons were made using two-sided paired t-tests for the comparison of mean MPOD values at baseline and at follow-up. Changes of MPOD over time (ΔMPOD) were calculated by subtracting values measured in MARS III from those measured at baseline in MARS II. Multivariate regression methods were applied to model ΔMPOD at 0.25°, 0.5°, 1.0° and 2.0° eccentricities in order to assess the impact of age at baseline, serum lutein/zeaxanthin levels, presence of AMD and presence of ring-like structure accounting for sex, BMI and self-reported intake of L/Z-containing supplements. In sensitivity analyses, pseudophakia and spherical equivalent were additionally included in the models. As smoking prevalence was extremely low among the aged participants of this study, we did not include smoking in the models. To account for the interrelation between the paired eyes in the study sample, we applied linear mixed regression modelling. In addition, we assessed if the presence of ring-like or intermediate structures changed between the two measurements. All analyses were performed using the Statistical Analysis System (SAS, version 9.4 for Windows, SAS Institute Inc., Cary, NC).
Baseline characteristics of the study
Number of study participants
Age at MARS II (years)
Number of study eyes
380 (100 %)
Number of eyes from females
244 (64.2 %)
150 (39.5 %)
230 (60.5 %)
87 (22.9 %)
69 (18.2 %)
224 (58.9 %)
Follow-up time (years)
Macular pigment optical density (MPOD, in density units D.U.) in the MARS II and MARS III examinations and their differences (ΔMPOD)
Predictors of the change of MPOD (ΔMPOD) after a median follow-up of 3.96 years; the results are presented as regression coefficients (β) from multivariate regression models
Change of MPOD (ΔMPOD)*
Age (per 5 years)
Log serum lutein [microg/ml] at follow-up
Log serum zeaxanthin [microg/ml] at follow-up
AMD (vs. none) at baseline
MPOD Ring (vs. none) at baseline
In this prospective study of elderly eyes, the levels of macular pigment increased only mildly (between 1.8 and 9.5 % relative change) over time and the spatial distribution was fairly stable. The MPOD increments were lower in eyes of older study participants, but this was statistically significant only at distances of 1.0° and 2.0° from the centre. Counterbalancing this was the effect of lutein in blood, presumably reflecting recent L/Z containing supplement use, raising MPOD levels also mainly in the perifoveal regions. The presence of early AMD or ring-like distributions at baseline had no obvious impact on MPOD alterations over time.
This is to our knowledge the first prospective observational study measuring MPOD changes in a cohort of elderly individuals who were not submitted to a study protocol involving systematic supplementation. The study cohort was reassessed after an average period of 4 years. We aimed to elucidate the process that may, at least in parts, reflect the ‘natural course’ of individual MPOD levels and distributions in elderly eyes due to ageing, environmental factors and disease. This study was observational and non-interventional by nature, permitting study individuals to start or stop the use of supplementary prescriptions indistinctively. The self-reported utilization of lutein and/or zeaxanthin containing supplements by study participants turned out to be highly variable probably due to recall errors. Supplements containing lutein and zeaxanthin in markedly varying concentrations are sold in Germany over the counter in pharmacies, drug stores and supermarkets—and their numbers count in hundreds. Therefore, the elderly participants could neither precisely recall brand names nor strengths of the supplement or duration of its intake. To corroborate the self-reported supplement use we measured the concentrations of lutein and zeaxanthin in serum at the time of the follow-up examination assuming that these concentrations more objectively reflected the individual situation with regard to recent supply with lutein and zeaxanthin. We observed that, even after controlling for self-reported supplement use at baseline and at follow-up, serum lutein concentrations were still significantly related to higher MPOD levels in the perifoveal region. By contrast, no MPOD changes were detected in the central foveal areas. These findings are in line with evidence showing lutein is predominantly stored in the perifoveal area  while zeaxanthin is stored in the fovea where it is presumably more stable and less easily influenced by supplementation  as also confirmed by a lack of associations with serum zeaxanthin in our study. This appears to also confirm previous reports postulating that the anatomical structure of the fovea plays an important role in the way MP is distributed . As suggested before , the rather stable central load of MP is presumably attributable to the xanthophyll binding Müller cell cones, while in the periphery the cone axons store the MP. It appears that raised serum lutein is more easily integrated in the peripheral axon membranes than in the Müller cones, probably because zeaxanthin dominates capacities in the latter. It would be interesting to determine whether this observation is entirely attributable to capacity of storage, micro-anatomical changes such as dislocations, crushing or squeezing of cell complexes, or whether degenerative processes influence the fluctuation of MPOD.
Of note, the average net change of MPOD over 4 years was, despite being statistically significant at the more peripheral eccentricities, quantitatively small. In an attempt to disentangle the influential factors in this process, we found a tendency of old eyes to accumulate less MP in the retinal periphery. In the overall summary analyses of all eyes, this was counterbalanced by the MPOD rise in the same region attributable to higher lutein serum concentrations. It appears that the utilization of MP containing supplements which was rising with age was leading to the positive net MPOD balance reported in Table 2.
Interestingly, and in line with previous findings [11, 13], the presence and magnitude of ring-like distributions of MPOD remained fairly stable over time. This supports the view that the spatial MPOD patterns are individually rather stable features and that they derive rather from anatomical and/or genetic predetermination than from the influence of lifestyles, age or the availability of carotenoids. Nevertheless, we observed variations in that some eyes with a ring were classified at follow-up as intermediate (15/87) while some appeared as ‘incident’ ring structures. This variability may potentially be attributable to the methods of classification of ring-like distributions from density profiles. These are dependent on the precise identification of the fovea center. However, the same technical equipment and the same trained observers carried out the analyses in this prospective study. The impact of surgical interventions (e.g., cataract removal) which may have improved the image quality between the first and the second examination was ruled out as a major biasing factor in sensitivity analyses.
Our finding that the presence of early AMD at baseline was prospectively unassociated with MPOD change seems to indicate that the onset of AMD is not accompanied by a concomitant marked loss of MP.
Previous studies suggested that the reasons for lower MPOD levels are female sex, smoking, ethnicity and older age . In this prospective study sex was unrelated to MPOD change over time and the impact of age was only very modest; the impact of smoking could not be assessed due to the low number of current smokers, and all participants were Caucasian. Thus, it may appear that MPOD levels and distribution in well-nourished elderly, avoiding nutritional depletion, is a stable and well conserved feature of the retina.
The strength of the presented report lies in its prospective design and the fact that measurements were repeated with consistent quality on a large number of eyes. As a major shortcoming we emphasize the difficulty of precisely and validly ascertaining the intake of supplements containing macular pigment components. Lutein levels in serum helped to account for this problem and we suppose that these measurements probably captured most of the influence of recent supplement utilization.
In conclusion, MPOD was rather stable in levels and spatial arrangement over time in ageing eyes. Significant MPOD rises predominating in the perifoveal regions probably indicate effects of lutein containing supplements. Eyes with early AMD showed no significant MPOD changes. The persistence of ring-like MPOD distributions over time seems to confirm previous reports suggesting that rings are mostly determined by anatomical structures.
changes of MPOD
age related macular degeneration
body mass index
Münster Ageing and Retina Study
macular pigment optical density
retinal pigment epithelium
HWH & DP originally planned and designed the study. MD performed study examinations. VMzW performed data clearance and set-up the data base. HWH & VMzW set up the data analysis plan and performed the analysis. VMzW drafted the manuscript. HWH, MD, MZ and VMzW edited the manuscript. All authors read and approved the final manuscript.
The authors would like to express their gratitude to all participants of the study for their time and consent to contribute and they thank Birte Claes for her technical assistance in data management.
The authors declare that they have no competing interests.
Availability of data and materials
The datasets supporting the conclusions of this article are included within the article and in the additional tables and figures. All further relevant data and materials will be shared on request.
Ethics approval and consent to participate
The recruitment and research protocols were reviewed and approved by the Institutional Review Boards of the University of Münster, and written informed consent was obtained from all study participants, in compliance with the Declaration of Helsinki.
MARS was sponsored by the Deutsche Forschungsgemeinschaft grants HE 2293/5-1, 2293/5-2, and 2293/5-3, by the ProRetina Foundation and the Intramural International Monetary Fund of the University of Münster. No financial disclosures were reported by the authors of this paper.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT. Epidemiology of age-related maculopathy: a review. Eur J Epidemiol. 2003;18:845–54.View ArticlePubMedGoogle Scholar
- Dietzel M, Pauleikhoff D, Arning A, et al. The contribution of genetic factors to phenotype and progression of drusen in early age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2014;252:1273–81.View ArticlePubMedGoogle Scholar
- Farwick A, Dasch B, Weber BH, Pauleikhoff D, Stoll M, Hense HW. Variations in five genes and the severity of age-related macular degeneration: results from the Muenster aging and retina study. Eye (Lond). 2009;23:2238–44.View ArticleGoogle Scholar
- Farwick A, Wellmann J, Stoll M, Pauleikhoff D, Hense HW. Susceptibility genes and progression in age-related maculopathy: a study of single eyes. Invest Ophthalmol Vis Sci. 2010;51:731–6.View ArticlePubMedGoogle Scholar
- Ahmed SS, Lott MG, Marcus DM. The macular xanthophylls. Surv Ophthalmol. 2005;50:183–93.View ArticlePubMedGoogle Scholar
- Subczynski WK, Wisniewska A, Widomska J. Location of macular xanthophylls in the most vulnerable regions of photoreceptor outer-segment membranes. Arch Biochem Biophys. 2010;504:61–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Trieschmann M, Beatty S, Nolan JM, et al. Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: the LUNA study. Exp Eye Res. 2007;84:718–28.View ArticlePubMedGoogle Scholar
- Loane E, Kelliher C, Beatty S, Nolan JM. The rationale and evidence base for a protective role of macular pigment in age-related maculopathy. Br J Ophthalmol. 2008;92:1163–8.View ArticlePubMedGoogle Scholar
- Davies NP, Morland AB. Macular pigments: their characteristics and putative role. Prog Retin Eye Res. 2004;23:533–59.View ArticlePubMedGoogle Scholar
- Zeimer MB, Kromer I, Spital G, Lommatzsch A, Pauleikhoff D. Macular telangiectasia: patterns of distribution of macular pigment and response to supplementation. Retina. 2010;30:1282–93.View ArticlePubMedGoogle Scholar
- Meyer zu Westrup V, Dietzel M, Pauleikhoff D, Hense HW. The association of retinal structure and macular pigment distribution. Invest Ophthalmol Vis Sci. 2014;55:1169–75.View ArticlePubMedGoogle Scholar
- Zeimer M, Dietzel M, Hense HW, Heimes B, Austermann U, Pauleikhoff D. Profiles of macular pigment optical density and their changes following supplemental lutein and zeaxanthin: new results from the LUNA study. Invest Ophthalmol Vis Sci. 2012;53:4852–9.View ArticlePubMedGoogle Scholar
- Tariq A, Mahroo OA, Williams KM, et al. The heritability of the ring-like distribution of macular pigment assessed in a twin study. Invest Ophthalmol Vis Sci. 2014;55:2214–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Snodderly DM, Auran JD, Delori FC. The macular pigment. II. Spatial distribution in primate retinas. Invest Ophthalmol Vis Sci. 1984;25:674–85.PubMedGoogle Scholar
- Reichenbach A, Bringmann A. New functions of Muller cells. Glia. 2013;61:651–78.View ArticlePubMedGoogle Scholar
- Dietzel M, Zeimer M, Heimes B, Pauleikhoff D, Hense HW. The ringlike structure of macular pigment in age-related maculopathy: results from the Muenster Aging and Retina Study (MARS). Invest Ophthalmol Vis Sci. 2011;52:8016–24.View ArticlePubMedGoogle Scholar
- Dasch B, Fuhs A, Schmidt J, et al. Serum levels of macular carotenoids in relation to age-related maculopathy: the Muenster Aging and Retina Study (MARS). Graefes Arch Clin Exp Ophthalmol. 2005;243:1028–35.View ArticlePubMedGoogle Scholar
- Dasch B, Fuhs A, Behrens T, et al. Inflammatory markers in age-related maculopathy: cross-sectional analysis from the Muenster Aging and Retina Study. Arch Ophthalmol. 2005;123:1501–6.View ArticlePubMedGoogle Scholar
- Dietzel M, Zeimer M, Heimes B, Claes B, Pauleikhoff D, Hense HW. Determinants of macular pigment optical density and its relation to age-related maculopathy: results from the Muenster Aging and Retina Study (MARS). Invest Ophthalmol Vis Sci. 2011;52:3452–7.View ArticlePubMedGoogle Scholar
- van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT. The risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam study. Arch Ophthalmol. 2003;121:519–26.View ArticlePubMedGoogle Scholar
- Delori FC, Goger DG, Hammond BR, Snodderly DM, Burns SA. Macular pigment density measured by autofluorescence spectrometry: comparison with reflectometry and heterochromatic flicker photometry. J Opt Soc Am A Opt Image Sci Vis. 2001;18:1212–30.View ArticlePubMedGoogle Scholar
- Delori FC. Autofluorescence method to measure macular pigment optical densities fluorometry and autofluorescence imaging. Arch Biochem Biophys. 2004;430:156–62.View ArticlePubMedGoogle Scholar
- Trieschmann M, Spital G, Lommatzsch A, et al. Macular pigment: quantitative analysis on autofluorescence images. Graefes Arch Clin Exp Ophthalmol. 2003;241:1006–12.View ArticlePubMedGoogle Scholar
- Trieschmann M, Heimes B, Hense HW, Pauleikhoff D. Macular pigment optical density measurement in autofluorescence imaging: comparison of one- and two-wavelength methods. Graefes Arch Clin Exp Ophthalmol. 2006;244:1565–74.View ArticlePubMedGoogle Scholar
- Bone RA, Landrum JT, Fernandez L, Tarsis SL. Analysis of the macular pigment by HPLC: retinal distribution and age study. Invest Ophthalmol Vis Sci. 1988;29:843–9.PubMedGoogle Scholar
- Nolan JM, Stringham JM, Beatty S, Snodderly DM. Spatial profile of macular pigment and its relationship to foveal architecture. Invest Ophthalmol Vis Sci. 2008;49:2134–42.View ArticlePubMedGoogle Scholar
- Wagner-Schuman M, Dubis AM, Nordgren RN, et al. Race- and sex-related differences in retinal thickness and foveal pit morphology. Invest Ophthalmol Vis Sci. 2011;52:625–34.View ArticlePubMedPubMed CentralGoogle Scholar